Vlerick Expertise in Healthcare

 

26 results Number of Results per Page
  1. Horizon scanning in a demand-driven healthcare system

    Acting with foresight in times of budget austerity

    Horizon scanning is acknowledged to be one of the key components of a demand-driven healthcare system. In this Policy Paper we propose a two-stage structure and organisation of the back-end national part of the horizon scanning process still to be implemented. This will lead to healthcare budgets managed with better foresight, a necessity in the face of breakthrough, some potentially curing therapies coming at a high cost. Taking the Belgian national component of the proposed horizon scanning system to implementation will require a pilot to be carried out. This to test the internal and external validity of the proposed design.

  2. Gene therapy

    How to address the affordability challenge for advanced therapy medicinal products

    Advanced therapy medicinal products have the potential to offer a durable, life-changing therapeutic effect, possibly with a single administration, for patients who may have few or no alternative treatment options. However, our current Belgian healthcare system is not attuned to these breakthrough therapies, which require short-term substantial payment for potentially lifelong patient value. In collaboration with Inovigate and through dialogue with all stakeholders, Vlerick Business School presents a policy report that contains workable solutions for expensive but curing therapies.

  3. Healthcare Management Centre Research Report 2019

    Healthcare Management Centre - annual research report 2019

    In 2019, we conclude the fifth year of Vlerick Healthcare Management Centre’s operations. Building upon a strong MINOZ legacy of studying hospital operations, we continue to expand and deepen our reach into the full healthcare system. This annual research report gives an overview of achievements and published output.

  4. What is value-based healthcare?

    What is value-based healthcare?

    In this 'What Is' video, Healthcare Professor Brecht Cardoen and Finance Professor Filip Roodhooft explain what value-based healthcare is and what it means for the medical industry and the pharma industry.

  5. The importance of machine learning for oncology

    How do you analyse real-world data?

    There is a high demand for innovative cancer drugs. Yet their development is a complex and lengthy affair, longer and more expensive than that for conventional cancer treatments and with little chance of success. The drugs that do make it through need to be made available as soon as possible. The EMA (European Medicines Agency) has therefore created flexible forms of market authorisation, such as conditional authorisation and adaptive pathways. As speed must not come at the expense of safety, these drugs must be monitored even after they have been put into circulation. This is no easy task. Tine Geldof's doctorate demonstrates that advanced data analysis techniques such as machine learning may offer a solution.

  6. Multidisciplinary collaboration in drug discovery – how to make it work

    Drug development is a long and expensive process. On average it takes more than ten years to get a drug to market and precious few molecules coming out of the drug discovery phase make it to clinical trials. The performance of the discovery team and the choices they make, however, have a knock-on effect on the rest of the drug development process. Together with colleagues from academia and the industry, professor Zeynep Erden identified the conditions for effective cross-disciplinary collaboration and knowledge creation in drug discovery teams.

  7. Hospital of the Future

    What does the hospital of the future look like?

    Our healthcare is constantly evolving so as to meet the changing demands of patients. What does the hospital of the future look like? What is the future role of hospitals in the healthcare system? And how can all stakeholders prepare for it? The Flemish government entrusted researchers at the Leuven Institute for Healthcare Policy (LIGB) of KU Leuven and Vlerick Business School with finding an answer to these questions. The findings of their study were published in a green paper that serves as support for future policy decisions.

  8. Price of medication

    Medicines: how much should they cost?

    Although medical progress is allowing us to treat more and more diseases, innovative medicines tend to be expensive. Expenses are rising constantly in the healthcare sector as a result, putting accessibility and affordability under pressure. Which criteria does the Belgian Commission for Reimbursement of Medicines apply and what could be improved? These questions are answered in a study based on RIZIV data, in the framework of the Roche Chair at the Vlerick Healthcare Management Centre.

  9. Flexible working in hospitals

    Flexible working in hospitals: how to make it a success

    Flexible working is all the rage these days, and hospitals can't escape the trend either. The white paper ‘Flexible working in hospitals: OM and HRM perspective’ by our MINOZ research centre is the fruit of last year's efforts. It examines what flexible working means for the organisation and the employee, how the two perspectives can be brought into balance and which forms of flexible working are relevant for hospitals. Illustrated with practical examples, it offers food for thought for organisations which would like to introduce flexible working themselves.

  10. White paper priorities in healthcare

    Setting Priorities in Healthcare

    Healthcare organisations are under growing pressure to give patients better outcomes and add value for all stakeholders. And in recent years, there has been an increase in innovation across the sector – with the arrival of emerging technologies and pharmaceutical advances that have the potential to enhance the lives of patients around the world.

26 results Number of Results per Page